A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

Valentina Shakhnovich1,2, P Brian Smith3, Jeffrey T Guptill3

  • 1The Children's Mercy Hospital, Kansas City, MO, USA. vshakhnovich@cmh.edu.

Paediatric Drugs
|August 12, 2018
PubMed

Insights

Obese children have reduced pantoprazole clearance, but current weight-tiered dosing achieves therapeutic exposures. Further research is needed due to significant inter-individual variability in pantoprazole area under the curve.

Area of Science:

  • Pharmacology
  • Pediatric Gastroenterology
  • Pharmacokinetics

Background:

  • Obese children are at high risk for acid-related diseases, yet pharmacokinetic data for proton pump inhibitors (PPIs) are limited.
  • Previous studies indicated decreased total body weight-adjusted pantoprazole clearance in obese children.

Purpose of the Study:

  • To develop a population pharmacokinetic (PopPK) model for pantoprazole in obese children.
  • To evaluate pantoprazole dosing strategies for obese pediatric patients using simulation.

Main Methods:

  • Utilized pharmacokinetic data from a prospective study of 40 obese children (aged 6-17 years).
  • Developed a two-compartment PopPK model using NONMEM, incorporating CYP2C19 genotype and total body weight.
  • Evaluated model performance via bootstrapping and predictive checks; simulated exposures for common dosing scenarios.

Main Results:

  • The best-fit PopPK model identified CYP2C19 genotype and total body weight as significant covariates.
  • Obese children exhibited significantly reduced weight-normalized pantoprazole clearance (CL/F) compared to existing data.
  • The FDA-approved weight-tiered dosing strategy achieved therapeutic pantoprazole exposures (AUC0-∞) without over- or under-prediction.

Conclusions:

  • Current FDA-approved weight-tiered dosing for pantoprazole is supported for obese children.
  • Empiric dose escalation of PPIs in obese children is not recommended based on these findings.
  • Significant inter-individual variability (3- to 5-fold) in pantoprazole AUC0-∞ persists with current dosing.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
307
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
570
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
279
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
249
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
758